MX2021009055A - Pauta posológica y método para tratar la hipertensión arterial pulmonar con rodatristat etilo. - Google Patents
Pauta posológica y método para tratar la hipertensión arterial pulmonar con rodatristat etilo.Info
- Publication number
- MX2021009055A MX2021009055A MX2021009055A MX2021009055A MX2021009055A MX 2021009055 A MX2021009055 A MX 2021009055A MX 2021009055 A MX2021009055 A MX 2021009055A MX 2021009055 A MX2021009055 A MX 2021009055A MX 2021009055 A MX2021009055 A MX 2021009055A
- Authority
- MX
- Mexico
- Prior art keywords
- arterial hypertension
- pulmonary arterial
- treating pulmonary
- ethyl
- rodatristat
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
Landscapes
- Health & Medical Sciences (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Physiology (AREA)
- Nutrition Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Pulmonology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Abstract
Se proporciona una pauta posológica diaria para tratar la hipertensión arterial pulmonar. La pauta asume la forma de dos formas farmacéuticas discretas. Cada forma farmacéutica incluye una cantidad de aproximadamente 600 mg a aproximadamente 800 mg de 8-(2-amino-6-((R)-1-(5-cloro-[1,1'- bifenil]-2-il)-2,2,2-triflu oroetoxi)pirimidin-4-il)-2,8- diazaespiro[4.5]decano-3-carboxilato de (S)-etilo. También existe otro método para proporcionar una pauta posológica diaria. También se proporcionan varios métodos para tratar la hipertensión arterial pulmonar. Se proporciona un método para reducir el nivel de biosíntesis de serotonina en al menos un 50 %. También se proporciona un método para lograr una AUC0-tau de = 2530 ng·h/ml de ácido (S)-8-(2-amino-6-((R)-1-(5-clo ro- [1,1'-bifenil]-2-il)-2,2,2-trifluoroetoxi)pirimidin-4-il)- 2,8-diazaespiro[4.5]decano-3-carboxílico. Se proporciona un método para lograr una reducción >50 % del 5-HIAA en orina.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962798827P | 2019-01-30 | 2019-01-30 | |
| PCT/IB2020/000074 WO2020157577A1 (en) | 2019-01-30 | 2020-01-30 | A dosage regime and method for treating pulmonary arterial hypertension with rodatristat ethyl |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2021009055A true MX2021009055A (es) | 2021-10-22 |
Family
ID=70285725
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2021009055A MX2021009055A (es) | 2019-01-30 | 2020-01-30 | Pauta posológica y método para tratar la hipertensión arterial pulmonar con rodatristat etilo. |
Country Status (9)
| Country | Link |
|---|---|
| US (2) | US11607413B2 (es) |
| EP (1) | EP3917531A1 (es) |
| JP (1) | JP2022518944A (es) |
| KR (1) | KR20210133953A (es) |
| CN (1) | CN113557022A (es) |
| AU (1) | AU2020213746A1 (es) |
| CA (1) | CA3128327A1 (es) |
| MX (1) | MX2021009055A (es) |
| WO (1) | WO2020157577A1 (es) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MX2021005559A (es) * | 2018-11-14 | 2021-09-10 | Altavant Sciences Gmbh | Compuesto espirocíclico cristalino, forma de dosificación que lo contiene, procedimiento de uso en el tratamiento de una enfermedad y procedimiento de recristalización. |
| WO2020099926A1 (en) | 2018-11-16 | 2020-05-22 | Altavant Sciences Gmbh | A method for treating pulmonary arterial hypertension and associated pulmonary arterial hypertension |
| CA3128327A1 (en) | 2019-01-30 | 2020-08-06 | Altavant Sciences Gmbh | A dosage regime and method for treating pulmonary arterial hypertension with rodatristat ethyl |
| JP2022525202A (ja) * | 2019-03-15 | 2022-05-11 | アルタバント・サイエンシズ・ゲーエムベーハー | 肺動脈性肺高血圧症および各種疾患に伴う肺動脈性肺高血圧症の治療法と１日あたりの投薬量 |
| WO2023062595A1 (en) | 2021-10-14 | 2023-04-20 | Altavant Sciences Gmbh | Treatment of subjects having pulmonary arterial hypertension with rodatristat ethyl |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2008275179B2 (en) | 2007-07-11 | 2013-09-12 | Lexicon Pharmaceuticals, Inc. | Methods and compositions for treating pulmonary hypertension and related diseases and disorders |
| UA119247C2 (uk) | 2013-09-06 | 2019-05-27 | РОЙВЕНТ САЙЕНСИЗ ҐмбГ | Спіроциклічні сполуки як інгібітори триптофангідроксилази |
| MX2021005559A (es) | 2018-11-14 | 2021-09-10 | Altavant Sciences Gmbh | Compuesto espirocíclico cristalino, forma de dosificación que lo contiene, procedimiento de uso en el tratamiento de una enfermedad y procedimiento de recristalización. |
| WO2020099926A1 (en) | 2018-11-16 | 2020-05-22 | Altavant Sciences Gmbh | A method for treating pulmonary arterial hypertension and associated pulmonary arterial hypertension |
| US20200188398A1 (en) | 2018-12-17 | 2020-06-18 | Altavant Sciences Gmbh | Method for treating sarcoidosis-associated pulmonary hypertension |
| WO2020128614A1 (en) | 2018-12-17 | 2020-06-25 | Altavant Sciences Gmbh | Method for treating interstital lung disease |
| CA3128327A1 (en) | 2019-01-30 | 2020-08-06 | Altavant Sciences Gmbh | A dosage regime and method for treating pulmonary arterial hypertension with rodatristat ethyl |
| JP2022525202A (ja) * | 2019-03-15 | 2022-05-11 | アルタバント・サイエンシズ・ゲーエムベーハー | 肺動脈性肺高血圧症および各種疾患に伴う肺動脈性肺高血圧症の治療法と１日あたりの投薬量 |
-
2020
- 2020-01-30 CA CA3128327A patent/CA3128327A1/en active Pending
- 2020-01-30 CN CN202080016400.5A patent/CN113557022A/zh active Pending
- 2020-01-30 EP EP20718760.0A patent/EP3917531A1/en not_active Withdrawn
- 2020-01-30 JP JP2021544351A patent/JP2022518944A/ja active Pending
- 2020-01-30 KR KR1020217024232A patent/KR20210133953A/ko unknown
- 2020-01-30 US US16/777,458 patent/US11607413B2/en active Active
- 2020-01-30 MX MX2021009055A patent/MX2021009055A/es unknown
- 2020-01-30 WO PCT/IB2020/000074 patent/WO2020157577A1/en unknown
- 2020-01-30 AU AU2020213746A patent/AU2020213746A1/en active Pending
-
2023
- 2023-01-25 US US18/159,494 patent/US20240041877A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| JP2022518944A (ja) | 2022-03-17 |
| US11607413B2 (en) | 2023-03-21 |
| WO2020157577A1 (en) | 2020-08-06 |
| CN113557022A (zh) | 2021-10-26 |
| WO2020157577A8 (en) | 2020-10-15 |
| US20200237759A1 (en) | 2020-07-30 |
| CA3128327A1 (en) | 2020-08-06 |
| KR20210133953A (ko) | 2021-11-08 |
| EP3917531A1 (en) | 2021-12-08 |
| US20240041877A1 (en) | 2024-02-08 |
| AU2020213746A1 (en) | 2021-08-19 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2021009055A (es) | Pauta posológica y método para tratar la hipertensión arterial pulmonar con rodatristat etilo. | |
| CA2281562C (en) | Forskolin for promoting lean body mass | |
| MX2021011224A (es) | Un método para tratar la hipertensión arterial pulmonar y la hipertensión arterial pulmonar asociada y pauta posológica diaria. | |
| US7666872B2 (en) | Use for PDE5 inhibitors | |
| US9937195B2 (en) | Edible energy composition | |
| US20170274002A1 (en) | Multiple folate formulation and use thereof | |
| CA3119909A1 (en) | A method for treating pulmonary arterial hypertension and associated pulmonary arterial hypertension | |
| WO1993010787A1 (en) | Methods and compositions for treating sleep disorders, convulsive seizures, and other disorders using optically pure (+) zopiclone | |
| US20230121312A1 (en) | Aldose reductase inhibitors for treating sorbitol dehydrogenase deficiency | |
| AU2019364274A1 (en) | Novel uses | |
| US5217974A (en) | Method for treating gar-transformylase tumors in mammals and reducing mammalian toxicity | |
| JP4604515B2 (ja) | 眼科用剤 | |
| EP3403512B1 (en) | Nonalcoholic fitness beverage | |
| JPH085791B2 (ja) | 抗白内障剤 | |
| CN111019902A (zh) | 一种前列腺癌多西他赛耐药细胞株的构建方法 | |
| AU640524B2 (en) | Use of folic acid for reducing the toxicity of antitumour antifolate agents and methods for treating tumours | |
| KR101841553B1 (ko) | 오르니친 또는 오르니친 염을 포함하는 성기능 개선용 조성물 | |
| Mittelman et al. | Adrenocortical response during corrected and uncorrected hypercapnic acidosis | |
| Bougle et al. | Plasma kinetics of parenteral tocopherol in premature infants | |
| CA1181694A (fr) | Compositions pharmaceutiques contenant de l'almitrine | |
| US11369651B2 (en) | Uses of FU-LING (Poria cocos) extract and tumulosic acid in protecting muscles | |
| Sasaki et al. | Stimulatory effect of Coca-Cola TM on gastroduodenal HCO 3− secretion in rats | |
| WO1993010788A1 (en) | Methods and compositions for treating sleep disorders, convulsive seizures, and other disorders using optically pure (-) zopiclone | |
| US20210121469A1 (en) | Edible Energy Composition | |
| RU2016150783A (ru) | Использование производного соединения тиохромено[2,3-с]хинолин-12-она для лечения немелкоклеточного рака легких |